Abstract
Anxiety disorders, such as post-traumatic stress (PTSD), panic, and phobic disorders, can be conceptualized as a failure to inhibit inappropriate fear responses. A common, effective treatment strategy involves repeated presentations to the feared cue without any danger (extinction). However, extinction learning has a number of important limitations, and enhancing its effects, generalizability and durability via cognitive enhancers may improve its therapeutic impact. In this review we focus specifically on the role of the cannabinoid system in fear extinction learning and its retention. We address the following questions: What are the neural circuits mediating fear extinction?; Can we make fear extinction more effective?; Can cannabinoids facilitate fear extinction in humans?; How might the cannabinoid system effect fear extinction? Collectively, translational evidence suggest that enhancing cannabinoid transmission may facilitate extinction learning and its recall, and that the cannabinoid system is a potential pharmacological target for improving the active learning that occurs during exposure-based behavioral treatments prompting future research in terms of mechanisms research, novel treatment approaches (‘cognitive enhancers’), and pharmacotherapeutic drug discovery.
Keywords: Cannabinoid, fear extinction, cognitive enhancer, ventromedial prefrontal cortex, hippocampus, amygdala, anxiety.
Current Pharmaceutical Design
Title:Cannabinoid Modulation of Fear Extinction Brain Circuits: A Novel Target to Advance Anxiety Treatment
Volume: 20 Issue: 13
Author(s): Christine A. Rabinak and K. Luan Phan
Affiliation:
Keywords: Cannabinoid, fear extinction, cognitive enhancer, ventromedial prefrontal cortex, hippocampus, amygdala, anxiety.
Abstract: Anxiety disorders, such as post-traumatic stress (PTSD), panic, and phobic disorders, can be conceptualized as a failure to inhibit inappropriate fear responses. A common, effective treatment strategy involves repeated presentations to the feared cue without any danger (extinction). However, extinction learning has a number of important limitations, and enhancing its effects, generalizability and durability via cognitive enhancers may improve its therapeutic impact. In this review we focus specifically on the role of the cannabinoid system in fear extinction learning and its retention. We address the following questions: What are the neural circuits mediating fear extinction?; Can we make fear extinction more effective?; Can cannabinoids facilitate fear extinction in humans?; How might the cannabinoid system effect fear extinction? Collectively, translational evidence suggest that enhancing cannabinoid transmission may facilitate extinction learning and its recall, and that the cannabinoid system is a potential pharmacological target for improving the active learning that occurs during exposure-based behavioral treatments prompting future research in terms of mechanisms research, novel treatment approaches (‘cognitive enhancers’), and pharmacotherapeutic drug discovery.
Export Options
About this article
Cite this article as:
Rabinak A. Christine and Phan Luan K., Cannabinoid Modulation of Fear Extinction Brain Circuits: A Novel Target to Advance Anxiety Treatment, Current Pharmaceutical Design 2014; 20 (13) . https://dx.doi.org/10.2174/13816128113199990437
DOI https://dx.doi.org/10.2174/13816128113199990437 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?
Current Aging Science The Importance of Ch / π Interactions to the Function of Carbohydrate Binding Proteins
Protein & Peptide Letters Development and Validation of a Liquid-Liquid Extraction and Gas Chromatography/Mass Spectrometry Methodology for Cannabidiol Analysis in Human Plasma
Current Pharmaceutical Analysis Editorial (Thematic Issue: Targeting Phosphodiesterases (PDEs) for Treatment of CNS Diseases)
Current Pharmaceutical Design Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Strategies to Overcome or Circumvent P-Glycoprotein Mediated Multidrug Resistance
Current Medicinal Chemistry Recent Progress in Machine Learning-based Prediction of Peptide Activity for Drug Discovery
Current Topics in Medicinal Chemistry In Silico Modeling of the α7 Nicotinic Acetylcholine Receptor: New Pharmacological Challenges Associated with Multiple Modes of Signaling
Mini-Reviews in Medicinal Chemistry Parental Tobacco Control in the Child Healthcare Setting
Current Pediatric Reviews Mechanism of Action and Potential Use of Tamoxifen in the Treatment of Acute Mania
Current Psychopharmacology Pathogenesis of Alzheimer Disease: Role of Oxidative Stress, Amyloid-β Peptides, Systemic Ammonia and Erythrocyte Energy Metabolism
CNS & Neurological Disorders - Drug Targets C-1073 (Mifepristone) in the Adjunctive Treatment of Alzheimers Disease
Current Alzheimer Research Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Message from the Editor-in-Chief
CNS & Neurological Disorders - Drug Targets The Vitamin D Neuroendocrine System as a Target for Novel Neurotropic Drugs
CNS & Neurological Disorders - Drug Targets MicroRNAs as Modulators of the Platelet Proteome
Current Proteomics ULK1 Plays a Critical Role in AMPK-Mediated Myocardial Autophagy and Contractile Dysfunction following Acute Alcohol Challenge
Current Pharmaceutical Design Role of Flavonoids in Neurodegenerative Diseases: Limitations and Future Perspectives
Current Topics in Medicinal Chemistry Endothelial Progenitor Cells Dysfunction and Senescence: Contribution to Oxidative Stress
Current Cardiology Reviews Development of RET Kinase Inhibitors for Targeted Cancer Therapy
Current Medicinal Chemistry